Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / February / Malignant Colossus
Cytology Microscopy and imaging Professional Development

Malignant Colossus

A closer look at cellular scale in lung adenocarcinoma cytology

By Jessica Allerton 02/11/2026 Gallery 0 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Top Thought Leaders

Share

Clinical Report: Malignant Colossus

Overview

This report discusses a photomicrograph of a large malignant cell from an EBUS-guided FNA cytology of lung adenocarcinoma. The findings underscore the importance of accurate cytological evaluation in lung cancer diagnosis.

Background

Lung adenocarcinoma is a prevalent form of lung cancer that often requires precise diagnostic techniques for effective management. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a critical procedure for obtaining cytological samples from suspected lung malignancies. Understanding the characteristics of malignant cells can aid in the development of targeted treatment strategies.

Data Highlights

No numerical data available in the source material.

Key Findings

  • The photomicrograph illustrates an exceptionally large malignant cell from lung adenocarcinoma.
  • EBUS-TBNA is the preferred method for diagnosing and staging lung cancer.
  • Rapid on-site evaluation during EBUS-TBNA can enhance diagnostic yield.
  • Comprehensive biomarker profiling is essential for guiding treatment in lung adenocarcinoma.
  • PD-L1 testing is crucial for determining immunotherapy options in lung cancer patients.

Clinical Implications

Healthcare professionals should prioritize the use of EBUS-TBNA for accurate lung cancer diagnosis and staging. Additionally, integrating biomarker profiling and PD-L1 testing into clinical practice can significantly influence treatment decisions and improve patient outcomes.

Conclusion

The evaluation of malignant cells through advanced cytological techniques is vital for the effective management of lung adenocarcinoma. Continued emphasis on diagnostic accuracy and biomarker assessment will enhance therapeutic strategies.

References

  1. Labiano T., Image of the Month, 2024 -- Malignant Colossus
  2. Pediatric Inflammatory Myofibroblastic Tumors of the Colon: Clinical Features, Treatment Approaches, and Outcomes—A Case Study with a Comprehensive Literature Review
  3. The ASCO Post — Fear of the Unknown: Cancer Treatment Can Be Scarier than the Disease Itself
  4. Journal of Neuro-Oncology — Case Study and Literature Analysis of Primary Diffuse Leptomeningeal Glioblastoma
  5. Blood Cancer Journal — Multi-Omics Analysis of Three Hematological Cancers in a Patient Identifies Their Origin from Clonal Hematopoietic Stem Cells
  6. EBUS transbronchial needle samples | Interventional Pulmonary - American College of Chest Physicians
  7. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025 - PubMed
  8. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC - PubMed

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Jessica Allerton

Deputy Editor, The Pathologist

More Articles by Jessica Allerton

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Intense Intestines
Microscopy and imaging
Intense Intestines

January 19, 2024

1 min read

Some powerful fluorescent microscopy in this Image of the Month…

Context Matters in Cancer Biology
Microscopy and imaging
Context Matters in Cancer Biology

December 27, 2021

1 min read

Akoya is leading the way with spatial phenotypic signatures – a novel class of biomarkers for predicting response to immunotherapy

When Pathology Goes 3D
Microscopy and imaging
When Pathology Goes 3D

February 2, 2022

1 min read

Stratifying cancers with non-destructive 3D pathology

Sacrificing Safety for Speed?
Microscopy and imaging
Sacrificing Safety for Speed?

February 4, 2022

3 min read

Wide adaptation of antigen testing could increase the risk of exposure to infectious SARS-CoV-2 samples

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.